Gergely Németh
Biographic Data
| ID | 8399426 |
|---|---|
| NAME | Gergely Németh |
| GIVEN NAMES | Gergely |
| FAMILY NAME | Németh |
| SIGNATURE | NÉMETH G |
| ORCID | 0000-0002-1590-2133 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 0 |
Medicine price transparency and confidential managed-entry agreements in Europe
Pricing of pharmaceuticals is an all-time challenge for healthcare systems. Often public payers agree with companies on confidential managed-entry agreements (MEAs) that, e.g. foresee discounts under specific circumstances. The EURIPID Executive Committee surveyed 22 European countries, who all reported the use of confidential agreements between pharmaceutical companies and public payers, confirming that the actual prices paid are typically lower…
No prominent works on this page.
Medicine price transparency and confidential managed-entry agreements in Europe
Pricing of pharmaceuticals is an all-time challenge for healthcare systems. Often public payers agree with companies on confidential managed-entry agreements (MEAs) that, e.g. foresee discounts under specific circumstances. The EURIPID Executive Committee surveyed 22 European countries, who all reported the use of confidential agreements between pharmaceutical companies and public payers, confirming that the actual prices paid are typically lower…
Accounting (1 work) · Business (1 work) · Confidentiality (1 work) · Economics (1 work) · Health Systems, Economic Evaluations, Quality of Life (1 work) · Law (1 work) · Pharmaceutical Economics and Policy (1 work) · Pharmaceutical industry and healthcare (1 work) · Political science (1 work) · Public disclosure (1 work)